We found extensive loss of AQP4 and GFAP immunoreactivity in the basal ganglia and corpus callosum around the injection site 24 h after intracerebral injection of NMO-IgG and hC (Fig. 1c). The gene discussed is GFAP; the disease is neuromyelitis optica.